In a report released today, Mark Massaro from Canaccord Genuity maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), with a price target of $70. The company’s shares closed yesterday at $62.46, close to its 52-week high of $63.60.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 16.8% and a 62.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Orasure Technologies, and Idexx Laboratories.
Currently, the analyst consensus on Exact Sciences is Strong Buy and the average price target is $66.50, representing a 6.5% upside.
In a report issued on May 30, Jefferies also maintained a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $63.60 and a one-year low of $31.04. Currently, Exact Sciences has an average volume of 2.24M.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EXAS in relation to earlier this year. Most recently, in March 2018, Graham Peter Lidgard, the CSO of EXAS bought 7,163 shares for a total of $99,995.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EXACT Sciences Corp. is a molecular diagnostics company, which is focused on the early detection and prevention of colorectal cancer. It has an intellectual property, which protects its non invasive, molecular screening technology for the detection of colorectal cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
